CCL5 and familial pancreatic carcinoma: In summary, we have identified multiple cytokines as potential predictive and pharmacodynamic biomarkers for VT1021 in patients with GBM and pancreatic cancer, with PAI-1, CH13L1 and CCL5 possibly serving as both predictive and pharmacodynamic biomarkers for VT1021.